Ascenta Capital Announces Final Close of $325 Million Inaugural Fund to Back Development-Stage Biotechs
Ascenta Capital (“Ascenta”), a venture firm investing in multi-medicine development-stage biotechnology companies, today announced the $325 million close of its inaugural fund (the “Fund”).
